DOJ Charges 455 People Over $6.5B Health Care Fraud Takedown

25th Jun 2026
The Department of Justice has used its 2026 National Health Care Fraud Takedown to send a sharper message to health-care providers, insurers and compliance teams: billing fraud is now being pursued as a joined criminal, civil and administrative enforcement problem, not merely as a reimbursement dispute. The June 23 announcement said 455 defendants, including 90 doctors and other licensed medical professionals, have been charged over alleged health-care fraud and opioid-abuse schemes involving more than $6.5 billion in false claims. The scale matters because the cases reach across Medicare, Medicaid, TRICARE and private health-care benefit programmes, with prosecutors pointing to alleged conduct that went well beyond inflated invoices. The Justice Department said the takedown involved cases in 56 federal districts and 45 U.S. states and territories, supported by 50 state Medicaid Fraud Control Units. Acting Attorney General Todd Blanche placed the exercise in whole-of-government terms, while the FBI, the Centers for Medicare & Medicaid Services and the Department of Health and Human Services Office of Inspector General each carried enforcement weight beyond the criminal indictments. The regulatory significance is that this is not only a criminal charging exercise. CMS said it has suspended 1,079 providers and revoked billing privileges for 1,403 providers, while HHS-OIG pursued civil monetary penalty activity, provider exclusions and payments to the Medicare Trust Fund. The Drug Enforcement Administration has also sought revocation of controlled-substance authority in 928 administrative cases since October 1, 2025, making the takedown a licensing and operational risk event for health-care businesses as well as a prosecution story. Health-care in-house teams now face a more joined-up enforcement risk, with agencies treating weak provider oversight, aggressive billing models and poor clinical documentation as connected warning signs. The District of Arizona charges over amniotic wound allografts, the Southern District of Florida case involving cardiovascular testing for student athletes, and the California hospice allegations over deceased Medicare beneficiaries show how clinical judgment, marketing, kickbacks and records creation can be tested together. A billing practice that once looked like a revenue-cycle issue can quickly become evidence in a fraud, false-claims or patient-harm case. The next stage of enforcement is likely to be driven by data. The Justice Department’s Fraud Division and CMS have agreed to use CMS data environments for advanced analytics and artificial-intelligence tools, while separate arrangements with the Department of Homeland Security and the Federal Trade Commission are aimed at breaking down data silos. That will matter to hospital systems, physician groups and private equity-backed providers because enforcement may increasingly begin with payment anomalies before a whistleblower or patient complaint reaches investigators. CMS, HHS-OIG and the Justice Department will now expect counsel advising Medicare and Medicaid providers to prove that billing controls, medical-necessity review and provider monitoring are working before data-led enforcement turns those weaknesses into criminal, civil or exclusion exposure.